candesartan cilexetil has been researched along with Cardiac Toxicity in 1 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on-treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines." | 5.24 | Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. ( Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Norseth, J; Omland, T; Ree, AH; Røsjø, H; Steine, K, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gulati, G | 1 |
| Heck, SL | 1 |
| Røsjø, H | 1 |
| Ree, AH | 1 |
| Hoffmann, P | 1 |
| Hagve, TA | 1 |
| Norseth, J | 1 |
| Gravdehaug, B | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Omland, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol[NCT01434134] | Phase 2 | 130 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for candesartan cilexetil and Cardiac Toxicity
| Article | Year |
|---|---|
Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antibiotics, | 2017 |